Dermatofibrosarcoma protuberans: an analysis of proliferative activity, DNA flow cytometry and p53 overexpression with emphasis on its progression
- PMID: 10504551
- DOI: 10.1046/j.1440-1827.1999.00944.x
Dermatofibrosarcoma protuberans: an analysis of proliferative activity, DNA flow cytometry and p53 overexpression with emphasis on its progression
Abstract
The aim of this study is to evaluate the degree and spectrum of malignancy of dermatofibrosarcoma protuberans (DFSP) in the aspect of proliferative activity, flow cytometric DNA analysis, and p53 immunoreactivity. Twenty-three tumors from 19 cases of DFSP including three cases of DFSP with fibrosarcomatous areas (DFSP-FS) were studied in comparison with its allied fibrohistiocytic tumors; that is, dermatofibroma (DF; 46 cases), fibrosarcoma (FS; four cases), and malignant fibrous histiocytoma (MFH; 11 cases). MIB-1 labeling index (LI) of DFSP was significantly higher than that of DF and was lower than those of FS and of MFH. In ordinary DFSP, the recurrent tumors exhibited significantly higher MIB-1 LI than that of the primary tumors, whereas the primary tumors showed almost the same proliferative activity of DF. DFSP-FS tended to have a higher proliferative activity than DFSP without FS-area (ordinary DFSP). In five of 19 cases of DFSP, aneuploidy (near-diploidy) was found in four recurrent and one primary tumors. Immunohistochemical p53 overexpression was found in three of 19 cases of DFSP which also showed higher proliferative activity and aneuploidy. All cases of DF were immunohistochemically negative for p53, but most of the cases of FS and MFH were positive. Although DFSP has been classified in a category of fibrohistiocytic tumor of intermediate malignancy, the recurrent DFSP, DFSP-FS, and DFSP with aneuploidy and/or p53 overexpression could be a subgroup of DFSP with more aggressive clinical behavior than ordinary primary ones.
Similar articles
-
Dermatofibrosarcoma protuberans with fibrosarcomatous areas. Molecular abnormalities of the p53 pathway in fibrosarcomatous transformation of dermatofibrosarcoma protuberans.Virchows Arch. 1998 Oct;433(4):323-9. doi: 10.1007/s004280050256. Virchows Arch. 1998. PMID: 9808434
-
A progression to dermatofibrosarcoma protuberans with a fibrosarcomatous component: a special reference to the chromosomal aberrations.Pathol Res Pract. 1999;195(7):451-60. doi: 10.1016/S0344-0338(99)80048-X. Pathol Res Pract. 1999. PMID: 10448661
-
[Fibrosarcomatous dermatofibrosarcoma protuberans: a clinicopathological analysis of 12 cases].Zhonghua Bing Li Xue Za Zhi. 2013 Nov;42(11):753-7. Zhonghua Bing Li Xue Za Zhi. 2013. PMID: 24447553 Chinese.
-
Dermatofibroma and dermatofibrosarcoma protuberans: differential expression of CD34 and factor XIIIa.Am J Dermatopathol. 1994 Oct;16(5):573-4. doi: 10.1097/00000372-199410000-00022. Am J Dermatopathol. 1994. PMID: 7528477 Review. No abstract available.
-
[Pigmented fibrosarcomatous dermatofibrosarcoma protuberans (Bednar tumor). 3 case reports, analogy with the "conventional" type and review of the literature].Pathologica. 1997 Jun;89(3):264-73. Pathologica. 1997. PMID: 9380420 Review. Italian.
Cited by
-
Expression of MMP-2, MMP-9 and MMP-11 in dermatofibroma and dermatofibrosarcoma protuberans.Kaohsiung J Med Sci. 2012 Oct;28(10):545-9. doi: 10.1016/j.kjms.2012.04.017. Epub 2012 Aug 27. Kaohsiung J Med Sci. 2012. PMID: 23089320 Free PMC article.
-
Dermatofibrosarcoma protuberans and small bowel adenocarcinoma: coincidental occurrence or genetic association?Int J Gastrointest Cancer. 2006;37(4):146-8. doi: 10.1007/s12029-007-9000-0. Int J Gastrointest Cancer. 2006. PMID: 18175227
-
Reconstructive Surgery in the Elderly: A Case Report on Maintaining the Quality of Life in a Patient with Vulvar Dermatofibrosarcoma Protuberans.Diseases. 2024 Nov 22;12(12):299. doi: 10.3390/diseases12120299. Diseases. 2024. PMID: 39727629 Free PMC article.
-
Current Update on the Molecular Biology of Cutaneous Sarcoma: Dermatofibrosarcoma Protuberans.Curr Treat Options Oncol. 2019 Mar 14;20(4):29. doi: 10.1007/s11864-019-0628-3. Curr Treat Options Oncol. 2019. PMID: 30874910 Review.
-
Clinicopathological features of fibrosarcomatous dermatofibrosarcoma protuberans and the construction of a back-propagation neural network recognition model.Orphanet J Rare Dis. 2021 Jan 26;16(1):48. doi: 10.1186/s13023-021-01698-4. Orphanet J Rare Dis. 2021. PMID: 33499900 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous